Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
ImmunityBio, Inc.
The study involves a Phase 1b dose escalation portion with up to 30 patients to determine the MTD (maximum tolerated dose) using a 3+3 dose escalation design and to designate a dose level for the Phase 2 expansion phase (RP2D). The Phase 2 portion of the study will consist of an expansion cohort of up to 39 patients receiving HCW9218 monotherapy at the RP2D level. An additional independent Phase 2 cohort of patients receiving HCW9218 at the RP2D level in sequence with gemcitabine and nab-paclitaxel will also be considered.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted